445 related articles for article (PubMed ID: 18081741)
21. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
22. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme.
Rossner S; Lange-Dohna C; Zeitschel U; Perez-Polo JR
J Neurochem; 2005 Jan; 92(2):226-34. PubMed ID: 15663471
[TBL] [Abstract][Full Text] [Related]
24. Cloning and expression of the rat BACE1 promoter.
Lange-Dohna C; Zeitschel U; Gaunitz F; Perez-Polo JR; Bigl V; Rossner S
J Neurosci Res; 2003 Jul; 73(1):73-80. PubMed ID: 12815710
[TBL] [Abstract][Full Text] [Related]
25. Translational control of BACE1 may go awry in Alzheimer's disease.
Wong PC
Neuron; 2008 Dec; 60(6):941-3. PubMed ID: 19109900
[TBL] [Abstract][Full Text] [Related]
26. APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.
Bettens K; Brouwers N; Engelborghs S; Van Miegroet H; De Deyn PP; Theuns J; Sleegers K; Van Broeckhoven C
Hum Mutat; 2009 Aug; 30(8):1207-13. PubMed ID: 19462468
[TBL] [Abstract][Full Text] [Related]
27. Calcium-dependent expression of TNF-alpha in neural cells is mediated by the calcineurin/NFAT pathway.
Canellada A; Cano E; Sánchez-Ruiloba L; Zafra F; Redondo JM
Mol Cell Neurosci; 2006 Apr; 31(4):692-701. PubMed ID: 16458016
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
29. A novel beta-site amyloid precursor protein cleaving enzyme (BACE) isoform regulated by nonsense-mediated mRNA decay and proteasome-dependent degradation.
Tanahashi H; Tabira T
Neurosci Lett; 2007 Nov; 428(2-3):103-8. PubMed ID: 17961921
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional regulation of BACE1 by NFAT3 leads to enhanced amyloidogenic processing.
Mei Z; Yan P; Tan X; Zheng S; Situ B
Neurochem Res; 2015 Apr; 40(4):829-36. PubMed ID: 25663301
[TBL] [Abstract][Full Text] [Related]
31. Activation of the Wnt/β-catenin pathway represses the transcription of the β-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter.
Parr C; Mirzaei N; Christian M; Sastre M
FASEB J; 2015 Feb; 29(2):623-35. PubMed ID: 25384422
[TBL] [Abstract][Full Text] [Related]
32. Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells.
Li Q; Wu D; Zhang L; Zhang Y
Exp Gerontol; 2010 Nov; 45(11):842-7. PubMed ID: 20600777
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of BACE1 stimulates spontaneous basal secretion in PC12 cells.
Lee HW; Seo HS; Ha I; Chung SH
Neurosci Lett; 2007 Jun; 421(2):178-83. PubMed ID: 17566645
[TBL] [Abstract][Full Text] [Related]
34. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.
Chen CH; Zhou W; Liu S; Deng Y; Cai F; Tone M; Tone Y; Tong Y; Song W
Int J Neuropsychopharmacol; 2012 Feb; 15(1):77-90. PubMed ID: 21329555
[TBL] [Abstract][Full Text] [Related]
35. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
Stockley JH; O'Neill C
Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
37. BACE1 expression and activity: relevance in Alzheimer's disease.
Zacchetti D; Chieregatti E; Bettegazzi B; Mihailovich M; Sousa VL; Grohovaz F; Meldolesi J
Neurodegener Dis; 2007; 4(2-3):117-26. PubMed ID: 17596706
[TBL] [Abstract][Full Text] [Related]
38. Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT.
Mackenzie GG; Oteiza PI
J Cell Physiol; 2007 Jan; 210(1):246-56. PubMed ID: 17044076
[TBL] [Abstract][Full Text] [Related]
39. Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: co-operation with Src tyrosine kinase.
Obasanjo-Blackshire K; Mesquita R; Jabr RI; Molkentin JD; Hart SL; Marber MS; Xia Y; Heads RJ
Cardiovasc Res; 2006 Sep; 71(4):672-83. PubMed ID: 16828070
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer's disease-relevant genes and proteins.
Zuchner T; Schliebs R; Perez-Polo JR
J Neurochem; 2005 Oct; 95(1):20-32. PubMed ID: 16181410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
